Please visit insights.opentrons.com/ngs-automation for more information.
App note can now be downloaded here.
Genome analysis has led to a new era of precision medicine. Disease-related genetic alterations can now be detected in DNA fragments circulating in the bloodstream.
All cells shed DNA creating a tremendous opportunity for non-invasive disease detection. A single blood draw can reveal a person’s genetic predisposition to disease or even specific drug therapies. But deep knowledge requires powerful tools and precision is paramount to uncovering the genetic clues floating in our blood. We are developing novel genomic tools to reveal DNA alterations with unprecedented accuracy for clinical and research use.
Our team is passionate, experienced and looking to expand.
Advances in Genome Biology and Technology (AGBT)
June 6- 9, 2022
Avida Biomed to present a poster, Wednesday, June 8, 2022
Zero-PCR, UMI-independent targeted sequencing for accurate genomic profiling
Lavaging Poin-n-Seq technology, DNA target molecules are ligated to full-length sequencing adapters and captured without any amplification—before, or after enrichment. A sequencing-ready captured library is prepared with high uniformity for any intended targets in less than 4 hours. currently suitable for genotyping and genomic alteration detection in samples with adequate DNA input (>100 ng) and moderate Limit Of Detection (LOD) requirements (1%).
Poster ID: #554
American Society of Clinical Oncology (ASCO)
June 3-6, 2022. Chicago, IL
Avida to present poster
A novel NGS kit solution for multi-cancer early detection using circulating cell free DNA based methylation analysis.
New Liquid Biopsy Data at ASCO Highlights Commercial Push Into Early Cancer Detection
Detection of Colorectal Cancer (CRC) through Novel Dual Targeted Sequencing Solution that Enables Methylation and Genomic Alteration Analysis of Cell-Free DNA Without Sample Splitting
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract Number for Publication: 3043
Jun 4-8, 2021
Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting
Control/Tracking Number: 21-LB-5489-AACR
Activity: Late Breaking and Clinical Trials
Category and Subclass: CL11-04 Liquid biopsies: Circulating DNA
Apr 9-14, 2021
Avida to present performance of Point-n-Seq Kits at AGBT poster session
Two Birds with One Stone - Novel Unified Target Sequencing Enabling Methylation and Genomic Alteration Analysis of Cell-Free DNA Without Sample Splitting
3/2/2021 12:00-2:30pm PST
Avida Biomed presented Point-N-Seq, our new liquid biopsy NGS solution at ASCO on May 29th, 2020. Point-n-Seq is the first technology that can conduct a combined methylation and genomic alteration analysis without having to split samples. With an analytical sensitivity of 0.003%, a turnaround time of just 2 days at 1/5th of the sequencing cost, Point-n-Seq is a higher performing, more cost-effective technology poised to fill the gaps in existing NGS solutions. Results from our pilot study analyzing plasma collected from CRC patients and individuals with polyps suggest that Point-n-Seq is the ideal platform solution for screening and monitoring cancer at-scale.
May 29-31, 2020 Virtual Meeting
Avida Biomed to present promising performance data for its novel targeted methylation sequencing technology, Point-n-Seq, and pilot study of detecting early-stage cancer with plasma cfDNA at the 2020 American Association annual meeting for Cancer Research in San Diego
Session Category: Prevention Research
Session Title: Late-Breaking Research: Prevention, Early Detection, and Interception
June 22- 24, 2020
Virtual Meeting II, Sessions Available Online
40531 Encyclopedia Circle, Fremont, California 94538, United States